Loteprednol etabonate/tobramycin
Alternative Names: LE-T; LE-Tobramycin; Loteprednol etabonate 0.5% and tobramycin 0.3% ophthalmic suspension; Tobramycin/loteprednol etabonate; ZyletLatest Information Update: 22 May 2014
At a glance
- Originator Pharmos Corporation
- Class Aminoglycosides; Androstadienes; Eye disorder therapies
- Mechanism of Action Glucocorticoid receptor agonists; Protein 30S ribosomal subunit inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Ocular inflammation
Most Recent Events
- 05 Aug 2013 Bausch & Lomb has been acquired by Valeant Pharmaceuticals International
- 27 Oct 2007 Bausch and Lomb has been acquired by Warburg Pincus
- 27 Jan 2005 First global launch of loteprednol etabonate/tobramycin